newsfilter
← Latest News
GlobeNewswire·

Melinta Therapeutics Announces U.S. FDA Approval of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)

~ Approval Based on Positive Phase III Trial Results of BAXDELA for Treatment of CABP in Adults~ ~ Company Delays Launch of CABP Indication Until Further Visibility Into Liquidity Position ~ ...